Sanofi American Depositary Receipt (SNY)
Sanofi to Buy Vaccine Maker Dynavax in $2.2 Billion Deal
The cash deal seeks to strengthen the French drugmaker's immunization portfolio after it suffered setbacks in clinical trials.
SNY's Rare Disease Drug Efdoralprin Alfa Gets EMA's Orphan Drug Tag
Sanofi gains EMA Orphan Drug status for efdoralprin alfa, a phase II biologic for AATD-related emphysema with promising dosing data.
SNY Stock Down on Double Trouble With Multiple Sclerosis Drug
Sanofi shares slide after the FDA again delays its review of its MS drug tolebrutinib, and a phase III study fails to hit its primary endpoint.
South Korea's ADEL signs up to $1.04 billion Alzheimer's drug development deal with Sanofi
South Korea-based ADEL said late on Monday that it has entered a $1.04 billion partnership with French drugmaker Sanofi to develop and sell the biotech company's experimental Alzheimer's disease treatment.
Sanofi: Today's Tolebrutinib Setback Shouldn't Worry Shareholders - This Is Why
Sanofi faces a setback as tolebrutinib fails its Phase 3 PPMS trial, halting regulatory pursuit for this indication. Meanwhile, an approval decision on the candidate has also been delayed. SNY's growth remains robust, with Q3 sales up 7% YoY, net income up 10%, and Dupixent driving ~35% of total revenues. Despite pipeline disappointments, SNY expects high single-digit sales and low-double-digit EPS growth for 2025, supported by new drug launches.
Dren Bio to collaborate with Sanofi to develop autoimmune disease therapies for up to $1.7 billion
Dren Bio, a private biotech company, said on Monday it has entered into a strategic collaboration with Sanofi to develop therapies for autoimmune diseases in a deal worth up to $1.7 billion.
Sanofi stock slumps after two setbacks on multiple-sclerosis drug
Shares of Sanofi slumped on Monday as the French drugmaker said a U.S. regulatory review of its multiple-sclerosis drug won't be completed by the end of the year and that a trial for a different form of MS didn't succeed.
Sanofi flags delay in FDA's decision on tolebrutinib, shares fall
French pharmaceutical group Sanofi said on Monday the U.S. Food and Drug Administration's decision on its investigative drug to treat multiple sclerosis was expected to be delayed until the first quarter of 2026, from the previously communicated December 28.
Sanofi Multiple Sclerosis Drug Hit by Double Setback
A U.S. regulatory decision on tolebrutinib will again be delayed while a late-stage trial of the drug for a different form of the disease didn't hit its main goal.
Sanofi's Bleeding-Disorder Treatments Get Approval in China
Two bleeding disorder treatments for both chronic and acute conditions, Qfitlia and Cablivi, have been approved in China.
SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous Urticaria
Sanofi/Regeneron's Dupixent wins EU nod for chronic spontaneous urticaria, marking its seventh approved indication across inflammatory diseases in the EU.
Bristol Myers, Sanofi sued by Texas over Plavix
Texas Attorney General Ken Paxton sued Bristol Myers Squibb and Sanofi , accusing the drugmakers of failing to disclose that Plavix, which is used to prevent blood clots, does not work effectively for many patients.
